全文获取类型
收费全文 | 22347篇 |
免费 | 2881篇 |
国内免费 | 455篇 |
专业分类
耳鼻咽喉 | 131篇 |
儿科学 | 791篇 |
妇产科学 | 385篇 |
基础医学 | 1709篇 |
口腔科学 | 209篇 |
临床医学 | 2510篇 |
内科学 | 5634篇 |
皮肤病学 | 348篇 |
神经病学 | 1547篇 |
特种医学 | 369篇 |
外科学 | 2257篇 |
综合类 | 1746篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 5069篇 |
眼科学 | 777篇 |
药学 | 936篇 |
3篇 | |
中国医学 | 226篇 |
肿瘤学 | 1030篇 |
出版年
2024年 | 56篇 |
2023年 | 444篇 |
2022年 | 263篇 |
2021年 | 471篇 |
2020年 | 444篇 |
2019年 | 215篇 |
2018年 | 779篇 |
2017年 | 774篇 |
2016年 | 833篇 |
2015年 | 804篇 |
2014年 | 743篇 |
2013年 | 998篇 |
2012年 | 1263篇 |
2011年 | 2041篇 |
2010年 | 1238篇 |
2009年 | 1021篇 |
2008年 | 1151篇 |
2007年 | 1155篇 |
2006年 | 965篇 |
2005年 | 1089篇 |
2004年 | 1884篇 |
2003年 | 1677篇 |
2002年 | 1208篇 |
2001年 | 945篇 |
2000年 | 504篇 |
1999年 | 476篇 |
1998年 | 412篇 |
1997年 | 343篇 |
1996年 | 162篇 |
1995年 | 119篇 |
1994年 | 112篇 |
1993年 | 143篇 |
1992年 | 125篇 |
1991年 | 87篇 |
1990年 | 87篇 |
1989年 | 73篇 |
1988年 | 63篇 |
1987年 | 53篇 |
1986年 | 46篇 |
1985年 | 32篇 |
1984年 | 24篇 |
1983年 | 19篇 |
1982年 | 20篇 |
1981年 | 22篇 |
1980年 | 14篇 |
1977年 | 13篇 |
1975年 | 13篇 |
1974年 | 18篇 |
1968年 | 17篇 |
1928年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
Petra M.C. Callenbach Lise P.M. Pels Paul G.H. Mulder Wim H.J.P. Linssen Rob H.J.M. Gooskens Jan L. van der Zwan Oebele F. Brouwer For the SUM Trial Group 《European journal of paediatric neurology》2007,11(6):325-330
About 4-10% of children and adolescents suffer from migraine. In the last few years, several studies have been performed to assess the efficacy and safety of triptans for the acute treatment of migraine in children and adolescents. Only sumatriptan nasal spray has been approved for the treatment of acute migraine with or without aura in adolescents aged 12-17 years in Europe. This review describes the results of the studies with sumatriptan nasal spray that have been performed in children and adolescents, including a study performed in the Netherlands. 相似文献
142.
143.
144.
A. C. KEECH J. M. ARMITAGE K. R. WALLENDSZUS A. LAWSON A. J. HAUER S. E. PARISH R. COLLINS for the Oxford Cholesterol Study Group 《British journal of clinical pharmacology》1996,42(4):483-490
1It has been suggested that lipophilic HMG CoA reductase inhibitors, like lovastatin and simvastatin, may cause sleep disturbance.
2Six hundred and twenty-one patients at increased risk of coronary heart disease were randomized in a single centre to receive 40 mg daily simvastatin, 20 mg daily simvastatin or matching placebo. To assess the effects of prolonged use of simvastatin on nocturnal sleep quality and duration, a sleep questionnaire was administered to 567 patients (95% of 595 survivors) at an average of 88 weeks (range: 44–129 weeks) after randomization.
3The main outcome measures were sleep-related problems and use of sleep-enhancing medications reported during routine study follow-up visits, and responses to the sleep questionnaire about changes in sleep duration and about various sleep events during the preceding month.
4No differences were observed between the treatment groups in the frequency of sleep-related problems reported, in the proportion of follow-up visits at which such problems were reported, or in the use of sleep-enhancing medications. The numbers who stopped study treatment were similar in the different treatment groups, and no patient stopped principally because of insomnia. In response to the sleep questionnaire, there were no significant differences between the treatment groups in reports of various sleep events during the preceding month, except that slightly fewer patients allocated simvastatin reported waking often. No differences in sleep duration were observed.
5This placebo-controlled trial does not indicate any adverse effects of prolonged treatment with simvastatin on systematically sought measures of sleep disturbance. 相似文献
145.
Schmidt S.; Giessel R.; Bergis K. H.; Strojek K.; Grzeszczak W.; Ganten D.; Ritz E.; the Diabetic Nephropathy Study Group 《Nephrology, dialysis, transplantation》1996,11(9):1755-1761
BACKGROUND.: There is agreement that a family history of hypertension (HT),is a predictor for the risk of diabetic nephropathy (DN) inpatients with type 2 diabetes, and possibly also type 1 diabetes.It follows that genes related to the risk of hypertension mustalso be considered candidate genes for DN. The 235T allele ofthe angiotensinogen gene was found to be related to primaryHT. METHODS.: To examine whether it is predictive for DN as well, we examinedthe angiotensinogen gene polymorphism in 230 healthy local controls,423 patients with type 1 diabetes (n=180 with DN; n=243 withoutDN) and 663 patients with type 2 diabetes (n=310 with DN; n=353without DN). The angiotensinogen gene M235T polymorphism wasdetermined using PCR amplification. RESULTS.: The following results were obtained (i) no significant differenceof genotype distribution (type 1: MM/MT/TT(%) 27.6/57.2/15.2vs. 27.2/56.1/16.7 (P=0.92); type 2: MM/MT/TT (%) 31.7/48.2/20.1vs. 32.9/46.8/20.3 (P=0.93)) or allele frequencies (type 1:M 0.56 vs. 0.55 (P=0.795); type 2: M 0.56 vs. 0.56 (P=0.86))was found, between diabetic patients with or without DN, (ii)no difference was found between normotensive and hypertensivediabetic patients. CONCLUSION.: The data argue against a role of the angiotensinogen gene M235Tpolymorphism in the manifestation of diabetic nephropathy orhypertension in diabetic patients. 相似文献
146.
147.
用国产WD-L92型染料激光机,对56例,61眼施行激光虹膜透切术。其中40眼行周边虹膜透切术,完全切穿率为92.5%;9例白内障术后瞳孔上移行光学虹膜切除术疗效满意。对其它一些病例也取得一定疗效。认为染料激光具有输出功率大,能量及光斑可调的优点,易一次击穿虹膜,应用于虹膜透切术疗效肯定。 相似文献
148.
中国东北地区未经抗病毒治疗的HIV/AIDS患者HIV毒株的耐药基因变异研究 总被引:10,自引:0,他引:10
目的 研究我国东北地区未接受抗逆转录病毒治疗的HIV AIDS患者HIV毒株的逆转录酶和蛋白酶耐药变异情况 ,为开展大规模临床抗病毒药物治疗提供本底数据。方法 RT PCR和套式PCR扩增HIVpol区基因 ,双脱氧法测定逆转录酶和蛋白酶基因序列 ,与国际耐药数据库比对辨别耐药变异。结果 (1) 5 3例患者毒株亚型分析结果 :B′亚型 4 7例 ,B′ C亚型 4例 ,A、B亚型各 1例 ;(2 )未发现逆转录酶和蛋白酶原发耐药变异存在 ,但发现存在逆转录酶抑制剂继发变异 :M4 1L(1.9% )、I6 3M (1.9% )、L74I (1.9% )、S6 8G (1.9% )、V75L (3.8% )、V10 6I (1.9% )、I135L T (5 .7% )、V179D (7.5 % )和V189I (1.9% ) ,无症状感染者RT继发耐药变异出现率为 11.8% ,而艾滋病患者为5 2 .6 % (P <0 .0 1)。存在大量蛋白酶耐药继发变异V77I (88.7% )、L6 3P (86 .8% )、E35D (81% )、A71V(2 4 .5 % )、R4 1K (15 .1% )、L10I (9.4 % )、R5 7K (9.4 % )、D6 0E (9.4 % )、N37D (5 .7% )、G16E (3.8% )、I15V (1.9% )、M36I (1.9% )、K5 5R (1.9% )和L89M (1.9% )。未发现明显的亚型特异性耐药变异。结论 在中国东北地区未接受抗逆转录病毒治疗的HIV AIDS患者中未发现毒株逆转录酶和蛋白酶耐药原发变异 ,但大量继发耐药变异的存在提 相似文献
149.
PTSD症状自评量表的信效度初步评价 总被引:9,自引:6,他引:9
目的:编制创伤后应激障碍症状自评量表。方法:根据诊断标准和Kubany的痛苦事件量表相结合来编制量表;在284名大学生、87名受灾居民和70名消防官兵中进行信度和效度检验。结果:量表的一致性系数为0.88-0.94,重测信度为0.83-0.88,与SCL90的焦虑、抑郁和恐怖因子的相关性在0.73以上,与DSM-IV的诊断符合率在90%以上。结论:量表有很好的信效度.可以用于评估创伤后应激障碍的症状及其严重程度。 相似文献
150.
Massa O Iafusco D D'Amato E Gloyn AL Hattersley AT Pasquino B Tonini G Dammacco F Zanette G Meschi F Porzio O Bottazzo G Crinó A Lorini R Cerutti F Vanelli M Barbetti F;Early Onset Diabetes Study Group of the Italian Society of Pediatric Endocrinology Diabetology 《Human mutation》2005,25(1):22-27
Permanent neonatal diabetes mellitus (PNDM) is a rare condition characterized by severe hyperglycemia constantly requiring insulin treatment from its onset. Complete deficiency of glucokinase (GCK) can cause PNDM; however, the genetic etiology is unknown in most PNDM patients. Recently, heterozygous activating mutations of KCNJ11, encoding Kir6.2, the pore forming subunit of the ATP-dependent potassium (K(ATP)) channel of the pancreatic beta-cell, were found in patients with PNDM. Closure of the K(ATP) channel exerts a pivotal role in insulin secretion by modifying the resting membrane potential that leads to insulin exocytosis. We screened the KCNJ11 gene in 12 Italian patients with PNDM (onset within 3 months from birth) and in six patients with non-autoimmune, insulin-requiring diabetes diagnosed during the first year of life. Five different heterozygous mutations were identified: c.149G>C (p.R50P), c.175G>A (p.V59M), c.509A>G (p.K170R), c.510G>C (p.K170N), and c.601C>T (p.R201C) in eight patients with diabetes diagnosed between day 3 and 182. Mutations at Arg50 and Lys170 residues are novel. Four patients also presented with motor and/or developmental delay as previously reported. We conclude that KCNJ11 mutations are a common cause of PNDM either in isolation or associated with developmental delay. Permanent diabetes of non autoimmune origin can present up to 6 months from birth in individuals with KCNJ11 and EIF2AK3 mutations. Therefore, we suggest that the acronym PNDM be replaced with the more comprehensive permanent diabetes mellitus of infancy (PDMI), linking it to the gene product (e.g., GCK-PDMI, KCNJ11-PDMI) to avoid confusion between patients with early-onset, autoimmune type 1 diabetes. 相似文献